Clinical trials

Search our clinical trials

City of Hope is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a clinical trial for your cancer type at City of Hope Atlanta, Chicago or Phoenix.


32 Clinical Trials

The primary objective of this study for the safety run-in cohorts of the study is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel (safety run-in cohort 1), and sacituzumab govitecan (safety run-in cohort 2) in metastatic triple-negative breast cancer (mTNBC).

A phase 2, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with bevacizumab and folfiri versus bevacizumab and folfiri in previously treated advanced inoperable metastatic colorectal cancer.

An open-label, randomized, phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab vs. chemotherapy in the second-line treatment setting in patients with colorectal cancer with KRAS G12C mutation.

A phase 2 study of magrolimab combination therapy in patients with head and neck squamous cell carcinoma


Accepting new patients


Learn more at


This phase 2 trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body.

This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).

This is a global phase 2, multi-center, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.


Accepting new patients


Learn more at


An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with Epstein-Barr virus-positive (EBV+) relapsed/refractory lymphomas.

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.

This study is a phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (phase 1b) and patients with NRAS-mutated melanoma (phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.